Which has stronger earnings and valuation, IMM or MPH?

ImmuPharma is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuPharma N/A N/A -£2.51M -£0.37 N/A Mereo BioPharma Group plc (MPH.L) N/A N/A N/A -£128.00 N/A

Which has better valuation and earnings, FARN or IMM?

ImmuPharma is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Faron Pharmaceuticals Oy N/A N/A -£60.23M -£22.07 N/A ImmuPharma N/A N/A -£2.51M -£0.37 N/A

Which has preferable valuation and earnings, IMM or BVXP?

Bioventix has higher revenue and earnings than ImmuPharma. ImmuPharma is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuPharma N/A N/A -£2.51M -£0.37 N/A Bioventix £12.54M 6.58 £8.12M £140.52 11.24

Is IMM or BVXP more profitable?

ImmuPharma has a net margin of 3,519.56% compared to Bioventix's net margin of 59.30%. Bioventix's return on equity of 65.83% beat ImmuPharma's return on equity. Company Net Margins Return on Equity Return on Assets ImmuPharma 3,519.56% -353.21% -43.00% Bioventix 59.30% 65.83% 54.07%

Do analysts prefer IMM or 4BB?

4basebio has a consensus target price of GBX 1,400, suggesting a potential upside of 180.00%. Given 4basebio's stronger consensus rating and higher possible upside, analysts plainly believe 4basebio is more favorable than ImmuPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is IMM or 4BB more profitable?

ImmuPharma has a net margin of 3,519.56% compared to 4basebio's net margin of 0.00%. 4basebio's return on equity of -231.29% beat ImmuPharma's return on equity. Company Net Margins Return on Equity Return on Assets ImmuPharma 3,519.56% -353.21% -43.00% 4basebio N/A -231.29% -54.30%

Which has better earnings & valuation, IMM or ORPH?

Open Orphan has higher revenue and earnings than ImmuPharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuPharma N/A N/A -£2.51M -£0.37 N/A Open Orphan £34.71M 0.00 N/A N/A N/A

ImmuPharma (IMM) Competitors

GBX 4.10 -0.20 (-4.65%)

As of 10:19 AM Eastern

Compare

IMM vs. MPH, FARN, BVXP, 4BB, and ORPH

Should you buy ImmuPharma stock or one of its competitors? MarketBeat compares ImmuPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ImmuPharma include Mereo BioPharma Group plc (MPH.L) (MPH), Faron Pharmaceuticals Oy (FARN), Bioventix (BVXP), 4basebio (4BB), and Open Orphan (ORPH). These companies are all part of the "biotechnology" industry.

How does ImmuPharma compare to Mereo BioPharma Group plc (MPH.L)?

ImmuPharma (LON:IMM) and Mereo BioPharma Group plc (MPH.L) (LON:MPH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

6.1% of ImmuPharma shares are owned by institutional investors. 6.2% of ImmuPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ImmuPharma is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuPharma	N/A	N/A	-£2.51M	-£0.37	N/A
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A	-£128.00	N/A

ImmuPharma has a net margin of 3,519.56% compared to Mereo BioPharma Group plc (MPH.L)'s net margin of 0.00%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuPharma	3,519.56%	-353.21%	-43.00%
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A

In the previous week, ImmuPharma's average media sentiment score of 0.00 equaled Mereo BioPharma Group plc (MPH.L)'saverage media sentiment score.

Company	Overall Sentiment
ImmuPharma	Neutral
Mereo BioPharma Group plc (MPH.L)	Neutral

Summary

ImmuPharma beats Mereo BioPharma Group plc (MPH.L) on 4 of the 7 factors compared between the two stocks.

How does ImmuPharma compare to Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy (LON:FARN) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Faron Pharmaceuticals Oy has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, ImmuPharma has a beta of 3.02, indicating that its share price is 202% more volatile than the broader market.

ImmuPharma has a net margin of 3,519.56% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%
ImmuPharma	3,519.56%	-353.21%	-43.00%

In the previous week, Faron Pharmaceuticals Oy had 1 more articles in the media than ImmuPharma. MarketBeat recorded 1 mentions for Faron Pharmaceuticals Oy and 0 mentions for ImmuPharma. Faron Pharmaceuticals Oy's average media sentiment score of 0.75 beat ImmuPharma's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Overall Sentiment
Faron Pharmaceuticals Oy	Positive
ImmuPharma	Neutral

2.5% of Faron Pharmaceuticals Oy shares are held by institutional investors. Comparatively, 6.1% of ImmuPharma shares are held by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are held by insiders. Comparatively, 6.2% of ImmuPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ImmuPharma is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A
ImmuPharma	N/A	N/A	-£2.51M	-£0.37	N/A

Summary

ImmuPharma beats Faron Pharmaceuticals Oy on 7 of the 11 factors compared between the two stocks.

How does ImmuPharma compare to Bioventix?

ImmuPharma (LON:IMM) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

ImmuPharma has a beta of 3.02, meaning that its stock price is 202% more volatile than the broader market. Comparatively, Bioventix has a beta of 0.554, meaning that its stock price is 45% less volatile than the broader market.

ImmuPharma has a net margin of 3,519.56% compared to Bioventix's net margin of 59.30%. Bioventix's return on equity of 65.83% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuPharma	3,519.56%	-353.21%	-43.00%
Bioventix	59.30%	65.83%	54.07%

In the previous week, ImmuPharma's average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.

Company	Overall Sentiment
ImmuPharma	Neutral
Bioventix	Neutral

6.1% of ImmuPharma shares are held by institutional investors. Comparatively, 20.6% of Bioventix shares are held by institutional investors. 6.2% of ImmuPharma shares are held by company insiders. Comparatively, 6.2% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bioventix has higher revenue and earnings than ImmuPharma. ImmuPharma is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuPharma	N/A	N/A	-£2.51M	-£0.37	N/A
Bioventix	£12.54M	6.58	£8.12M	£140.52	11.24

Summary

Bioventix beats ImmuPharma on 8 of the 10 factors compared between the two stocks.

How does ImmuPharma compare to 4basebio?

ImmuPharma (LON:IMM) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

ImmuPharma has a beta of 3.02, suggesting that its stock price is 202% more volatile than the broader market. Comparatively, 4basebio has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

4basebio has a consensus target price of GBX 1,400, suggesting a potential upside of 180.00%. Given 4basebio's stronger consensus rating and higher possible upside, analysts plainly believe 4basebio is more favorable than ImmuPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuPharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

ImmuPharma has a net margin of 3,519.56% compared to 4basebio's net margin of 0.00%. 4basebio's return on equity of -231.29% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuPharma	3,519.56%	-353.21%	-43.00%
4basebio	N/A	-231.29%	-54.30%

In the previous week, ImmuPharma's average media sentiment score of 0.00 equaled 4basebio'saverage media sentiment score.

Company	Overall Sentiment
ImmuPharma	Neutral
4basebio	Neutral

6.1% of ImmuPharma shares are held by institutional investors. Comparatively, 0.9% of 4basebio shares are held by institutional investors. 6.2% of ImmuPharma shares are held by insiders. Comparatively, 12.1% of 4basebio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ImmuPharma has higher earnings, but lower revenue than 4basebio. ImmuPharma is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuPharma	N/A	N/A	-£2.51M	-£0.37	N/A
4basebio	£1.69M	45.73	-£9.84M	-£109.00	N/A

Summary

4basebio beats ImmuPharma on 7 of the 13 factors compared between the two stocks.

How does ImmuPharma compare to Open Orphan?

ImmuPharma (LON:IMM) and Open Orphan (LON:ORPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

In the previous week, ImmuPharma's average media sentiment score of 0.00 equaled Open Orphan'saverage media sentiment score.

Company	Overall Sentiment
ImmuPharma	Neutral
Open Orphan	Neutral

ImmuPharma has a net margin of 3,519.56% compared to Open Orphan's net margin of 0.00%. Open Orphan's return on equity of 0.00% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuPharma	3,519.56%	-353.21%	-43.00%
Open Orphan	N/A	N/A	N/A

6.1% of ImmuPharma shares are held by institutional investors. 6.2% of ImmuPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Open Orphan has higher revenue and earnings than ImmuPharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuPharma	N/A	N/A	-£2.51M	-£0.37	N/A
Open Orphan	£34.71M	0.00	N/A	N/A	N/A

Summary

ImmuPharma beats Open Orphan on 4 of the 7 factors compared between the two stocks.

Get ImmuPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMM vs. The Competition

Export

Metric	ImmuPharma	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£25.58M	£508.28M	£6.91B	£2.79B
Dividend Yield	0.77%	3.90%	2.68%	6.15%
P/E Ratio	-11.08	3.15	27.23	368.16
Price / Sales	N/A	6,285.40	573.53	84,675.68
Price / Cash	20.50	13.13	49.25	27.89
Price / Book	6.35	89.63	10.85	7.60
Net Income	-£2.51M	-£96.07M	£3.59B	£5.89B
7 Day Performance	1.36%	-1.89%	-2.26%	0.12%
1 Month Performance	-9.09%	1.13%	1.89%	-1.28%
1 Year Performance	100.00%	55.41%	23.86%	62.28%

ImmuPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMM ImmuPharma	N/A	GBX 4.10 -4.7%	N/A	+108.7%	£25.58M	N/A	N/A	13	Gap Down High Trading Volume
MPH Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A	N/A	£89.76M	N/A	N/A	50	Gap Down
FARN Faron Pharmaceuticals Oy	N/A	GBX 41.62 +0.3%	N/A	-79.6%	£84.20M	N/A	N/A	34	Gap Down
BVXP Bioventix	N/A	GBX 1,580 -1.3%	N/A	-43.4%	£83.60M	£12.54M	11.24	12
4BB 4basebio	N/A	GBX 550 +4.8%	GBX 1,400 +154.5%	-45.0%	£81.30M	£1.69M	N/A	101

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:IMM) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmuPharma (IMM) Competitors

IMM vs. MPH, FARN, BVXP, 4BB, and ORPH

How does ImmuPharma compare to Mereo BioPharma Group plc (MPH.L)?

Summary

How does ImmuPharma compare to Faron Pharmaceuticals Oy?

Summary

How does ImmuPharma compare to Bioventix?

Summary

How does ImmuPharma compare to 4basebio?

Summary

How does ImmuPharma compare to Open Orphan?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMM vs. The Competition

ImmuPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmuPharma (IMM) Competitors

IMM vs. MPH, FARN, BVXP, 4BB, and ORPH

How does ImmuPharma compare to Mereo BioPharma Group plc (MPH.L)?

Do institutionals & insiders believe in IMM or MPH?

Which has stronger earnings and valuation, IMM or MPH?

Is IMM or MPH more profitable?

Does the media prefer IMM or MPH?

Summary

How does ImmuPharma compare to Faron Pharmaceuticals Oy?

Which has more risk and volatility, FARN or IMM?

Is FARN or IMM more profitable?

Does the media favor FARN or IMM?

Do insiders and institutionals have more ownership in FARN or IMM?

Which has better valuation and earnings, FARN or IMM?

Summary

How does ImmuPharma compare to Bioventix?

Which has more volatility & risk, IMM or BVXP?

Is IMM or BVXP more profitable?

Does the media prefer IMM or BVXP?

Do institutionals and insiders believe in IMM or BVXP?

Which has preferable valuation and earnings, IMM or BVXP?

Summary

How does ImmuPharma compare to 4basebio?

Which has more volatility & risk, IMM or 4BB?

Do analysts prefer IMM or 4BB?

Is IMM or 4BB more profitable?

Does the media refer more to IMM or 4BB?

Do institutionals and insiders hold more shares of IMM or 4BB?

Which has better earnings and valuation, IMM or 4BB?

Summary

How does ImmuPharma compare to Open Orphan?

Does the media prefer IMM or ORPH?

Is IMM or ORPH more profitable?

Do institutionals and insiders have more ownership in IMM or ORPH?

Which has better earnings & valuation, IMM or ORPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMM vs. The Competition

ImmuPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools